• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Eye Issues Aren't Always Obvious

    10/1/25 8:30:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care
    Get the next $COO alert in real time by email

    The Canadian Association of Optometrists (CAO) urges regular comprehensive eye exams for children with a new awareness campaign.

    As we celebrate Children's Vision Month in October, the CAO is launching a new digital awareness campaign to address children's vision care and the rising epidemic of myopia.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251001096869/en/

    Raising public awareness about the importance of regular eye exams for early detection remains crucial to improving eye care outcomes for Canadians, from toddlers to seniors. Unfortunately, eye health often doesn't receive the same level of attention as other routine health care.

    "Many parents assume they would know if their child was struggling to see, and children with vision problems are generally unaware of their condition because they assume everyone sees the way they do", says Dr. Allison Scott, CAO President. "Parents are often surprised when optometrists diagnose their child with an ocular issue. Reassuring them, explaining that these things aren't always obvious, leads to a better understanding of the importance of regular comprehensive eye exams".

    CAO's new campaign aims to boost public awareness about children's vision care through a simple yet potent message: Eye issues aren't always obvious. It will run throughout October on Facebook, Instagram, YouTube, TikTok, Pinterest, and Spotify in English and French, and is supported by New Brunswick Association of Optometrists, Newfoundland and Labrador Association of Optometrists, Nova Scotia Association of Optometrists, and The Prince Edward Island Association of Optometrists, and industry sponsors - Alcon and CooperVision.

    It is never too soon to see an optometrist

    As a child grows, so do their eyes, and eye conditions can develop quickly. Optometrists frequently encounter ‘invisible' eye issues especially myopia or nearsightedness – an increasingly common eye disease among children.

    This is why the CAO recommends that parents schedule comprehensive eye exams for their children starting at six to nine months, then again between the ages of two and five years, and annually thereafter to age 19. After 19, eye development stabilizes, allowing eye exams every two years for healthy adults with no known eye conditions.

    Eye exams are crucial, even if no symptoms are evident, to catch potential issues early and ensure timely intervention.

    Fighting Myopia, one of the leading causes of vision loss in the world1

    Detecting myopia early on means taking measures right away to halt or slow the progression. People with myopia will have trouble seeing distant objects, such as road signs, whiteboards, movie screens and TVs. Myopia has both a genetic and environmental component, including increased near work and screen time among children.

    Research shows that myopia is occurring at earlier ages starting in childhood (6-7 years of age) and progressing at a more rapid rate than in previous generations. This is concerning, given that high levels of myopia can lead to sight-threatening conditions, including retinal detachments, cataracts, glaucoma, and myopic maculopathy. By 2050, the prevalence of myopia is estimated to increase to 50% of the world's population2.

    "We know that clear vision is the cornerstone of a child's ability to learn, grow, and build confidence," according to Vanessa Johari Hansen, Country Business Unit Head, Vision Care, at Alcon Canada. "Alcon is proud to support the Canadian Association of Optometrists' campaign, empowering families to prioritize regular comprehensive eye exams, so children can See Brilliantly and Learn Brilliantly."

    Focusing on prevention, early detection and timely treatment of vision problems set the foundation for lifelong eye health, and beyond.

    "Myopia can significantly impact a child's ability to engage fully in daily life, even in the short term. While correcting vision is important, it's only part of the solution. Myopia often progresses as children grow," said Enrique Contreras, Country Manager at CooperVision Canada. "As a global leader in myopia management for children, we are dedicated to offering innovative solutions designed to slow that progression, helping to reduce the risk of serious vision complications later in life."

    Maintaining good habits beyond the optometrist's exam room will also help minimize the impact of myopia. Spending more time outdoors and limiting screen time are beneficial for healthy development, both for ocular health as well as overall health.

    To find more about the CAO's new awareness campaign, please visit: https://opto.ca/eye-issues-not-obvious

    About the Canadian Association of Optometrists

    The Canadian Association of Optometrists (CAO) is the national voice of optometry. Optometrists are independent primary health care providers and represent the front line of vision health. Optometrists practice in a range of settings: most work in private practice, others work in clinics, hospitals, community health centres, corporate optometry, research, teaching, and administration. Recognized at home and internationally as a leading advocate for the profession, CAO provides leadership and support to its +8,400 members (Optometrists, Students, and Optometric Assistants) to enhance the delivery of healthy eyes and clear vision for all Canadians. For more information, visit www.opto.ca

    About Alcon

    Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.ca.

    About CooperVision

    CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric, and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit https://coopervision.ca.

    1 Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health. 2013;1(6):e339-49.

    2 Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-42.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251001096869/en/

    For media inquiries, please contact: Julie Vanghelder, Director, Communications & Marketing, [email protected]

    Get the next $COO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COO

    DatePrice TargetRatingAnalyst
    10/1/2025$64.00Sell
    Goldman
    8/28/2025$72.00Buy → Neutral
    Citigroup
    7/22/2025$92.00Neutral → Outperform
    BNP Paribas Exane
    6/17/2025$94.00Hold → Buy
    Needham
    5/30/2025$76.00Overweight → Neutral
    Analyst
    8/29/2024$115.00 → $120.00Overweight
    Piper Sandler
    7/16/2024$107.00 → $115.00Hold → Buy
    Jefferies
    3/19/2024$125.00Neutral → Buy
    Redburn Atlantic
    More analyst ratings

    $COO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eye Issues Aren't Always Obvious

    The Canadian Association of Optometrists (CAO) urges regular comprehensive eye exams for children with a new awareness campaign. As we celebrate Children's Vision Month in October, the CAO is launching a new digital awareness campaign to address children's vision care and the rising epidemic of myopia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251001096869/en/ Raising public awareness about the importance of regular eye exams for early detection remains crucial to improving eye care outcomes for Canadians, from toddlers to seniors. Unfortunately, eye health often doesn't receive the same level of attention as other routin

    10/1/25 8:30:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Expanded Share Repurchase Program

    SAN RAMON, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today its Board of Directors has approved a $1 billion increase in the Company's share repurchase program. The share repurchase program now totals $2 billion. "We are pleased to announce that our Board of Directors has authorized an increase to our share repurchase program," said Al White, President and Chief Executive Officer. "This decision underscores the strength of our balance sheet and cash flow generation, and reflects the Board's continued confidence in Cooper's long-term growth trajectory. Returning capital to our shareholders through share repurc

    9/17/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Third Quarter 2025 Results

    SAN RAMON, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2025. Revenue increased 6% year-over-year to $1,060.3 million. CooperVision (CVI) revenue up 6% to $718.4 million, and CooperSurgical (CSI) revenue up 4% to $341.9 million.GAAP diluted earnings per share (EPS) of $0.49, down $0.03 or 6% from last year's third quarter.Non-GAAP diluted EPS of $1.10, up $0.14 or 15% from last year's third quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, CooperCompanies' Presiden

    8/27/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kurzius Lawrence Erik bought $136,780 worth of shares (2,000 units at $68.39), increasing direct ownership by 53% to 5,777 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    9/29/25 8:36:52 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    President & CEO White Albert G Iii bought $683,900 worth of shares (10,000 units at $68.39), increasing direct ownership by 5% to 226,151 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    9/5/25 5:10:48 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    President, CooperVision, Inc. Warner Gerard H Iii bought $100,384 worth of shares (1,450 units at $69.23), increasing direct ownership by 9% to 18,319 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    9/5/25 4:07:15 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Cooper with a new price target

    Goldman initiated coverage of Cooper with a rating of Sell and set a new price target of $64.00

    10/1/25 8:47:38 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Cooper downgraded by Citigroup with a new price target

    Citigroup downgraded Cooper from Buy to Neutral and set a new price target of $72.00

    8/28/25 8:04:41 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Cooper upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Cooper from Neutral to Outperform and set a new price target of $92.00

    7/22/25 7:47:24 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kurzius Lawrence Erik bought $136,780 worth of shares (2,000 units at $68.39), increasing direct ownership by 53% to 5,777 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    9/29/25 8:36:52 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    President & CEO White Albert G Iii bought $683,900 worth of shares (10,000 units at $68.39), increasing direct ownership by 5% to 226,151 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    9/5/25 5:10:48 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    President, CooperVision, Inc. Warner Gerard H Iii bought $100,384 worth of shares (1,450 units at $69.23), increasing direct ownership by 9% to 18,319 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    9/5/25 4:07:15 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    SEC Filings

    View All

    SEC Form 10-Q filed by The Cooper Companies Inc.

    10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)

    8/28/25 4:18:56 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 8-K filed by The Cooper Companies Inc.

    8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

    8/27/25 4:25:57 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SD filed by The Cooper Companies Inc.

    SD - COOPER COMPANIES, INC. (0000711404) (Filer)

    5/30/25 4:20:18 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Leadership Updates

    Live Leadership Updates

    View All

    CooperCompanies Appoints Barbara Carbone to Board of Directors

    SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

    4/30/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Evolus Announces Appointment of Albert G. White III to Board of Directors

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

    7/1/24 8:00:00 AM ET
    $COO
    $EOLS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CooperCompanies Appoints Lawrence E. Kurzius to Board of Directors

    SAN RAMON, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) announced today that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023. Kurzius has also been appointed to serve on the Audit Committee and Organization & Compensation Committee when he joins the Board. "We are thrilled to welcome Lawrence to our Board of Directors," said Al White, President and CEO. "His track record of successfully leading a complex, multinational organization will be extremely valuable to CooperCompanies as we continue to drive global growth at CooperVision and CooperSurgical." Kurzius served as Chief Executive Officer of McCo

    11/30/23 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Financials

    Live finance-specific insights

    View All

    CooperCompanies Announces Third Quarter 2025 Results

    SAN RAMON, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2025. Revenue increased 6% year-over-year to $1,060.3 million. CooperVision (CVI) revenue up 6% to $718.4 million, and CooperSurgical (CSI) revenue up 4% to $341.9 million.GAAP diluted earnings per share (EPS) of $0.49, down $0.03 or 6% from last year's third quarter.Non-GAAP diluted EPS of $1.10, up $0.14 or 15% from last year's third quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, CooperCompanies' Presiden

    8/27/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Release Date for Third Quarter 2025

    SAN RAMON, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report third quarter 2025 financial results on Wednesday, August 27, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 3665386. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beaut

    7/24/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Second Quarter 2025 Results

    SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2025. Revenue increased 6% year-over-year to $1,002.3 million. CooperVision (CVI) revenue up 5% to $669.6 million, and CooperSurgical (CSI) revenue up 8% to $332.7 million.GAAP diluted earnings per share (EPS) of $0.44, consistent with last year's second quarter.Non-GAAP diluted EPS of $0.96, up $0.11 or 14% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, CooperCompanies' President and CEO said,

    5/29/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/16/24 4:57:01 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G filed by The Cooper Companies Inc.

    SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/14/24 10:04:33 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/13/24 5:02:29 PM ET
    $COO
    Ophthalmic Goods
    Health Care